The American Academy of Neurology (AAN) Annual Meeting brings together an international attendance of the neurology committee to promote the highest quality patient-centered neurologic care, convey the latest advances, and enhance career satisfaction.
Preserving Cognitive Status in Pediatric Multiple Sclerosis: Kimberly O’Neill, MD
April 24th 2023The pediatric neuroimmunology fellow at NYU Langone provided perspective on a study presented at AAN 2023 comparing cognitive trajectories of pediatric and adult multiple sclerosis. [WATCH TIME: 3 minutes]
Long-term Ofatumumab Treatment Shows Freedom From Disease Progression, Favors Earlier Initiation
April 24th 2023The data, from the phase 3 ASCLEPIOS I and II trials and ALITHIOS open-label extension, suggest that most patients remained free from disease progression, with most progression being independent of relapse activity.
Eculizumab Safe and Effective in Adolescents With Myasthenia Gravis, Small-Scale Study Suggests
April 23rd 2023FDA-approved for adults with generalized myasthenia gravis in 2016, eculizumab continued to show promising efficacy and safety responses in adolescents with the disease, regardless of on concomitant use of IVIG.
Identifying Gaps in Access to Accurate Information on Epilepsy Surgery: Daniel Correa, MD, MSc
April 23rd 2023The neurologist at Montefiore Medical Center, Albert Einstein College of Medicine, provided insight on the need to improve online resources that provide epilepsy surgery information to patients. [WATCH TIME: 4 minutes]
Using Artificial Intelligence Applications in Neurology to the Field: Kathryn A. Davis, MD, MSc
April 22nd 2023The associate professor of neurology and director of the Penn Epilepsy Center at the University of Pennsylvania talked about the potential of using artificial intelligence in the field of neurology as part of an upcoming session at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]
Open-Label Analysis Highlights Long-Term Safety of BTK Inhibitor Tolebrutinib
April 22nd 2023There were no observed tolebrutinib dose effect for treatment-emergent adverse events in the double-blind portion, as well as no new safety signals seen for those who crossed over in the open-label extension.
Targeting Blood Vessels to Improve Treatment for Alzheimer Disease: Costantino Iadecola, MD
April 22nd 2023The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine talked about the importance of vascular health in preventing cognitive impairment as part of his presentation at the 2023 AAN annual meeting. [WATCH TIME: 6 minutes]
Advances in Neurology, Contributions to Brain Health: Costantino Iadecola, MD
April 20th 2023The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine talked about brain health in relation to vascular health ahead of the 2023 AAN annual meeting. [WATCH TIME: 3 minutes]
Analyzing Specific Pathways in Cells to Prevent Relapse in NMOSD: Shuhei Nishiyama, MD, PhD
April 19th 2023The research fellow at the Neuroimmunology Clinic and Research Laboratory, Massachusetts General Hospital and Harvard Medical School, talked about his research of cell function in NMOSD to be presented at the upcoming AAN annual meeting. [WATCH TIME: 6 minutes]
Specific Considerations for Monoclonal Antibody Treatment in NMOSD: Shuhei Nishiyama, MD, PhD
April 17th 2023The research fellow at the Neuroimmunology Clinic and Research Laboratory, Massachusetts General Hospital and Harvard Medical School, talked about having safer and more specific treatments for NMOSD that are antigen-specific. [WATCH TIME: 4 minutes]
Progress in Neurogenerative Disease Drug Development: Gregory A. Rippon, MD, MS
May 19th 2022The chief medical partner of neurology, ophthalmology, and internal medicine at Genentech shared his perspective on the steps the field has taken to improve clinical trials and therapies for neurodegenerative diseases such as Alzheimer disease. [WATCH TIME: 3 minutes]
Reactions to FDA Advisory Panel Decision on AMX0035: Justin Klee; Josh Cohen, BSc
May 19th 2022The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against evidence of efficacy for AMX0035 in ALS. [WATCH TIME: 3 minutes]
NeuroVoices: Mark Lew, MD, on the Validation of Tears as a Biomarker for Parkinson Disease
May 18th 2022The director of the Division of Movement Disorders at the USC Keck School of Medicine provided insight on the next steps to justify whether reflex tears are a reliable biomarker for Parkinson disease.
Validating Tears as a Biomarker in Atypical Presentations of Parkinson Disease: Mark Lew, MD
May 11th 2022The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the efforts needed to validate tears as a biomarker in patients who don’t present with typical Parkinson disease. [WATCH TIME: 4 minutes]